Vertex will bolster its inhouse manufacturing capabilities while adding three cell therapy approaches to type 1 diabetes through the acquisition of ViaCyte. In 2019, Vertex Pharmaceuticals entered the diabetes cell therapy space through the $950 million acquisition of Semma Therapeutics. The deal brought Vertex a stem cell-derived islet platform and VX-880, an allogeneic candidate for type 1 diabetes (T1D), entering the firm into the relatively small islet cell space. Now the firm plans to remove its main competition, ViaCyte, through…
